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ABSTRACT
Leukocyte adhesion deficiency (LAD)–1, a primary immunodeficiency disease caused by molecular defects in
the leukocyte integrin CD18 molecule, is characterized by recurrent, life-threatening bacterial infections.
Myeloablative hematopoietic stem cell transplantation is the only curative treatment for LAD-1. Recently,
canine LAD (CLAD) has been shown to be a valuable animal model for the preclinical testing of nonmyeloa-
blative transplantation regimens for the treatment of children with LAD-1. To develop new allogeneic
transplantation approaches for LAD-1, we assessed a nonmyeloablative conditioning regimen consisting of
busulfan as a single agent before matched littermate allogeneic bone marrow transplantation in CLAD. Three
CLAD dogs received busulfan 10 mg/kg intravenously before infusion of matched littermate bone marrow, and
all dogs received posttransplantation immunosuppression with cyclosporin A and mycophenolate mofetil.
Initially, all 3 dogs became mixed chimeras, and levels of donor chimerism sufficient to reverse the CLAD
phenotype persisted in 2 animals. The third dog maintained donor microchimerism with an attenuated CLAD
phenotype. These 3 dogs have all been followed up for at least 1 year after transplantation. These results
indicate that a nonmyeloablative conditioning regimen with chemotherapy alone is capable of generating stable
mixed chimerism and reversal of the disease phenotype in CLAD.
© 2005 American Society for Blood and Marrow Transplantation
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1NTRODUCTION
Leukocyte adhesion deﬁciency (LAD)–1 is a ge-
etic immunodeﬁciency disease that results from het-
rogeneous mutations in the leukocyte integrin CD18
olecule [1,2]. The inability of LAD-1 leukocytes to
dhere to the vessel wall and migrate to sites of infec-
ion as a result of CD18 mutations accounts for the
isease phenotype, which consists of episodes of life-
hreatening bacterial infection, leukocytosis with ma-
ure neutrophilia, advanced periodontal disease, and t
B&MTarkedly impaired wound healing. Depending on the
evel of expression of CD18, LAD-1 can be catego-
ized into moderate and severe phenotypes [3]. Chil-
ren with the severe-deﬁciency phenotype express less
han 1% of normal levels of CD18 and typically de-
elop lethal bacterial infections within the ﬁrst years
f life. Children with the moderate phenotype have
igher levels of CD18 expression in their cells (1%-
0% of normal levels) and survive into the second or
hird decade of life [3].
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7Allogeneic hematopoietic stem cell transplanta-
ion after myeloablative conditioning is currently the
nly deﬁnitive therapy for LAD-1 [4,5]. Historically,
he goal of myeloablative conditioning in this setting
s to achieve 100% donor chimerism. However, it
eems that complete donor chimerism is not required
or correction of the clinical phenotype in LAD-1.
nalysis of a small number of LAD-1 patients who
eveloped mixed donor chimerism after a myeloabla-
ive conditioning regimen indicates that the mixed
himeric state resulted in reversal of the disease phe-
otype [5]. These results suggest that a nonmyeloabla-
ive transplant regimen used to achieve mixed chimer-
sm may be effective in LAD-1, thus sparing the child
ith LAD-1 the regimen-related toxicity associated
ith myeloablation before transplantation [5].
We recently established a colony of mixed-breed
ogs with canine LAD (CLAD) to test new transplan-
ation approaches to this disease. CLAD represents
he canine equivalent of the severe-deﬁciency pheno-
ype of LAD-1 in children [6]. Puppies with CLAD
xperience recurrent life-threatening infections that
ypically culminate in death by 6 months of age [7,8].
LAD is due to a single DNA point mutation (G107C)
nd amino acid substitution (C36S) in the leukocyte
ntegrin CD18 subunit; this mutation results in the
nability to express the CD18 subunit on the leukocyte
urface [9]. In previous studies, we established that a
onmyeloablative transplantation regimen consisting
f 200 cGy of total body irradiation (TBI), infusion of
atched littermate bone marrow, and a short post-
ransplantation immunosuppressive regimen with cy-
losporin A (CsA) and mycophenolate mofetil (MMF)
esulted in stable mixed donor-host chimerism and
eversal of the CLAD phenotype [10].
This study assessed whether single-agent intrave-
ous busulfan could replace TBI in the nonmyeloab-
ative conditioning regimen. Two of the 3 CLAD
ogs treated with this regimen achieved levels of do-
or chimerism that reversed the disease phenotype.
he third dog has donor microchimerism with atten-
ation of the severe CLAD phenotype and remains
live more than 2 years after transplantation.
ATERIALS AND METHODS
ogs
All procedures involving animals in this study were
pproved by the Animal Care and Use Committee of
he National Cancer Institute (Bethesda, MD). These
tudies were conducted in accordance with the prin-
iples outlined in the Guide for the Care and Use of
aboratory Animals published by the National Re-
earch Council of the National Academy of Sciences.
nimals were housed in a facility accredited by the
ssociation for Assessment and Accreditation of Labo- C
56atory Animal Care, either on the campus of the Na-
ional Institutes of Health in Bethesda, MD, or at the
ational Institutes of Health satellite facility in
oolesville, MD.
All animals were immunized against common ca-
ine viral diseases and were monitored at least twice a
ay by the veterinary care staff. The temperature,
ulse, and respirations were recorded for each dog
rom 4 weeks of age until at least 4 months after
ransplantation. A veterinarian examined all dogs show-
ng signs of illness and prescribed treatment as clinically
ndicated. Fevers were managed with broad-spectrum
ntibiotics according to the results of culture and phys-
cal examination, and pain was treated with appropri-
te narcotic or nonnarcotic analgesics. Matched litter-
ate donor-recipient pairs were identiﬁed by using
ighly polymorphic microsatellite markers near the
og leukocyte antigen (DLA) loci in the major histo-
ompatibility complex, as previously described [8,11].
LAD Phenotype Identification
CLAD-affected dogs were identiﬁed by ﬂow cytom-
try of peripheral blood leukocytes by using anti-CD18
onoclonal antibodies (DakoCytomation, Carpinteria,
A) labeled with ﬂuorescein isothiocyanate to demon-
trate the absence of CD18 on the cell surface, as
reviously described [8]. This anti-human CD18 an-
ibody cross-reacts with canine CD18 [8,12].
one Marrow Harvests
Bone marrow was harvested from donors, and the
D34 cells were isolated as previously described
13,14]. Brieﬂy, marrow was aspirated from the bilat-
ral humeri, femora, and tibiae through Jamshidi nee-
les (Cardinal Health, Dublin, OH) while dogs were
nder general anesthesia. Up to 15 mL/kg donor
eight of marrow was aspirated into heparinized sy-
inges and ﬁltered by using a commercial bone mar-
ow collection kit according to the manufacturer’s
nstructions (Baxter Healthcare Corporation, Deer-
eld, IL). CD34 cells were quantiﬁed from an ali-
uot of marrow by using phycoerythrin-conjugated
onoclonal antibody 1H6 directed against canine
D34 (BDPharmingen, San Diego, CA) [15].
ransplantation Conditioning,
one Marrow Infusion, and
osttransplantation Immunosuppression
The 3 dogs that received matched littermate bone
arrow infusions underwent transplantation before 3
onths of age. Pretransplantation conditioning con-
isted of 10 mg/kg busulfan (Busulfex; ESP Pharma,
dison, NJ) administered intravenously over 1 hour
n day 2. This dose of busulfan has previously been
hown to be nonmyeloablative in healthy dogs [16].
LAD dogs were pretreated with 2 mg/kg diphenhy-
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Busulfan-Based Nonmyeloablative Bone Marrow Transplantation for CLAD
Bramine (Elkins-Sinn, Inc., Cherry Hill, NJ) and 0.22
g/kg ondansetron (Zofran; GlaxoSmithKline, Re-
earch Triangle Park, NC), both given intravenously
o reduce the incidence of emesis. On the day of
ransplantation, designated day 0, fresh unmanipu-
ated whole bone marrow was infused intravenously
ver 30 minutes.
Posttransplantation immunosuppression consisted
f CsA (Sandimmune; Novartis, East Hanover, NJ)
nd MMF (CellCept; Roche, Nutley, NJ). Recipient
ogs received 15 mg/kg CsA orally twice daily starting
n day 1 and continuing until day 35. From day
36 to day 65, CsA was given orally twice daily at
.5 mg/kg. MMF was given orally at 10 mg/kg twice
aily from day 0 until day 28.
linical Assessment and Posttransplantation Care
After transplantation, dogs were monitored clini-
ally twice a day for behavior, activity level, vital signs,
nd weight. A veterinarian examined all dogs showing
igns of illness and prescribed treatment as clinically
ndicated. Fevers were managed with broad-spectrum
ntibiotics according to the results of culture and phys-
cal examination. Pain was treated with appropriate nar-
otic or nonnarcotic analgesics. Complete blood counts
nd blood chemistry tests were evaluated weekly from
eeks 2 to 6, every two weeks from weeks 7 through
6, monthly from week 17 to week 52, and every 3
onths thereafter (or as clinically indicated).
himerism Analysis after Transplantation
Donor chimerism was quantiﬁed after transplanta-
ion by using ﬂow cytometry to detect donor CD18
eukocytes, as previously described [13]. Flow cytomet-
ic chimerism assays were performed weekly from
eeks 2 to 6, every two weeks from weeks 7 through
6, monthly from week 17 to week 52, and every 3
onths thereafter.
tatistics
Survival curves were calculated according to the
ethod of Kaplan and Meier [17]. The 2-tailed log-
ank test was used as a test of signiﬁcance.
ESULTS
linical Course of Control CLAD Dogs
CLAD dogs develop a constellation of clinical man-
festations of the disease starting at approximately 6
eeks of age [7,8]. Examples of these ﬁndings in our
olony are shown in Figure 1. Craniomandibular os-
eopathy and hypertrophic osteodystrophy (HOD) of
he extremities are noninfectious, inﬂammatory pro-
iferations of the bone of unknown etiology (Figure
A, B, and D). The gingivitis (Figure 1C) and non- r
B&MTealing wounds (not shown) in CLAD dogs mirror
ndings in young children with LAD-1 [18].
The 3 CLAD dogs in our colony that lacked a
atched littermate were euthanized after several
onths of life because of intractable symptoms of
LAD. Two of the CLAD dogs (Poliwag and Velma)
ere euthanized at 2 and 4 months of age, respec-
ively, because of severe HOD and craniomandibular
steopathy. The third dog (Cayenne) was euthanized
t 6 months of age because of severe recurrent skin
nfections associated with resistant microorganisms.
ecropsy reports of the 3 dogs showed lymphadenop-
thy, splenomegaly, HOD, marrow hyperplasia, mul-
iple dermal abscesses, tracheal ulcers, congestive neu-
rophilic hepatitis, jejunal abscess, or a combination of
hese (data not shown).
one Marrow Transplantation
Three CLAD dogs (Frodo, Billy, and Vixen) re-
eived transplants from matched littermate donors
efore 3 months of age. All 3 were symptomatic with
ever, infection, and/or HOD before transplantation.
ll 3 dogs received a nonmyeloablative conditioning
igure 1. Clinical manifestations of CLAD. A, Hypertrophy of the
uzzle due to craniomandibular osteopathy (CMO). The nasojeju-
al tube is used for total enteral nutrition and is necessitated by the
og’s inability to open its jaws fully because of CMO. The Eliza-
ethan collar is to prevent the dog’s removing an intravenous
atheter necessary for the administration of antibiotics. B, Foreleg
f a CLAD dog with HOD and carpal swelling. C, Gingivitis, likely
ue to a combination of CMO and oral infection. D, Forelimb
adiograph of a dog with HOD. The double physis sign, pathogno-
onic for HOD, is evident as lucent bands proximal to the femoral
nd distal to the tibial epiphyses.egimen consisting of 10 mg/kg busulfan administered
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7ntravenously over 1 hour and given 48 hours before
ransplantation (Figure 2). Details of the cell products
nfused are presented in Table 1. All 3 animals re-
eived 5  106 bone marrow CD34 cells per kilo-
ram (Table 1).
The transplantation regimen was well tolerated by
ll 3 dogs, with no infusional toxicity or regimen-
elated morbidity. The hematologic toxicity of the
ransplant regimen was mild, with a leukocyte nadir
mean  SD) of 8.8  0.4  103 cells per microliter
canine normal leukocyte range, 4-15.5 103 cells per
icroliter; Antech Diagnostics, Lake Success, NY).
latelet and hematocrit nadirs were 41  14  103
ells per microliter (normal range, 170-400 103 cells
er microliter) and 28.1%  1.37% (normal range,
6%-60%), respectively. No dog required transfu-
ional support.
Posttransplantation immunosuppression with CsA
as continued for 2 months, and MMF was continued
or 1 month (Figure 2). The major complication from
mmunosuppression with CsA and MMF was emesis.
sA also caused varying degrees of gingival hyperpla-
ia in all of the dogs; it resolved after completion of
mmunosuppression at day 65.
igure 2. Nonmyeloablative transplantation regimen for CLAD
sing busulfan. Three CLAD pups received busulfan 10 mg/kg
ntravenously on day 2. On day 0, bone marrow was harvested
rom matched littermate donors and infused intravenously into the
LAD pups. Dogs received immunosuppression with MMF 10
g/kg orally twice daily for 28 days and with CsA 15 mg/kg orally
wice daily for 35 days, and then they received 7.5 mg/kg orally
wice daily for 30 days. The peritransplantation day is shown on the
-axis. po indicates orally; iv, intravenously; bid, twice daily.
able 1. Details of CD34 Cell Transplantations and Clinical Outcom
Dog
Age at
Transplantation
(wk)
CD34 Cells
Infused
(/kg)
Length of
Follow-Up
(mo)
% o
Neutr
rodo 12 6.7  106 24 10.0
illie 10 17.1  106 24 0.0
ixen 10 12.3  106 12 8.6BC indicates white blood cells.
58ngraftment and Chimerism
All 3 CLAD dogs that received transplants initially
ngrafted. Two dogs, Frodo and Vixen, achieved sta-
le mixed donor-host chimerism: Frodo displayed do-
or chimerism of 15.9% CD18 donor leukocytes at
years after transplantation, and Vixen had 11.8%
D18 donor leukocytes 1 year after transplantation.
lthough Frodo and Vixen remain stable mixed chi-
eras, the percentage of CD18 donor-derived leu-
ocytes declined between approximately day 100 and
ay 350 before plateauing (Figure 3). A notable fea-
ure of both Frodo’s and Vixen’s posttransplantation
ourse is that the nonmyeloablative transplantation
esulted in a split lymphoid-myeloid chimerism. In
rodo’s case, CD3 chimerism is nearly 3-fold greater
han myeloid chimerism, with 47.5% donor CD3
ells in the peripheral blood (Table 1).
The third dog, Billie, displayed initial engraftment
ollowed by decreasing levels of CD18 donor-
erived leukocytes over the 2 months after transplan-
ation. This culminated in a state of donor microchi-
erism, with 0.64% of the peripheral blood leukocytes
f donor origin 24 months after transplantation (Table
; Figure 3).
linical Outcomes of Transplantations and
xtended Follow-up
Frodo and Billie are now 2 years after transplanta-
ion, and Vixen is 1 year after transplantation (Table 1).
rodo and Vixen are clinically indistinguishable from
naffected dogs (Figure 4). They are housed in stan-
ard conditions with other healthy dogs. Billie has had
ntermittent skin and gingival infections and receives
rophylactic oral antibiotics (Figure 4). Nevertheless,
his dog remains alive 2 years after transplantation,
arkedly exceeding the 6-month life expectancy of
LAD dogs that did not undergo transplantation in our
tudies and others [7,10]. None of the 3 CLAD dogs that
eceived transplants developed acute or chronic graft-
ersus-host disease (GVHD) after matched littermate
llotransplantation. As compared with the control
ogs, dogs that underwent transplantation had signif-
AD Dogs after Busulfan Conditioning
 Leukocytes at Last
Follow-Up WBC Count at
Last Follow-Up
(/L)
Clinical Status at
Last Follow-Up
CD3
Lymphocytes Total
47.5% 15.9% 11 000 Alive and well
3.12% 0.64% 24 400 Alive on
prophylactic
antibiotics
22.0% 11.8% 10 800 Alive and welles in CL
f CD18
ophils
%
3%
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Busulfan-Based Nonmyeloablative Bone Marrow Transplantation for CLAD
Bcantly improved survival (Figure 5; P  .025 by 2-
ailed log-rank test).
There is no standard laboratory measurement of
LAD disease activity; however, the peripheral blood
eukocyte count serves as a surrogate marker for
LAD [8]. Of the dogs presented here, Frodo and
ixen have resolved leukocytosis, with white blood
ell counts of 11 000 and 10 800 cells per microliter at
04 and 52 weeks after transplantation, respectively,
hereas Billie’s total white blood cell counts have
emained increased, at 24 000 cells per microliter at 97
eeks after transplantation, predominantly as a result
f a mature neutrophilia. Neutrophilia is a typical
igure 3. Leukocyte chimerism after transplantation. Blood was co
eukocytes were isolated and stained with either an anti-CD18 mo
ethods.”
igure 4. Clinical course of CLAD dogs that received transplants.
s described in “Materials and Methods.” The day of transplantat
ndicated by ﬁlled circles. The day of birth is indicated by a black diamon
B&MTnding in CLAD dogs. The clinical outcomes of the
ransplantations are summarized in Table 1.
ISCUSSION
We have demonstrated that a nonmyeloablative
one marrow transplantation regimen consisting of
retransplantation conditioning with busulfan, along
ith a brief course of posttransplantation immunosup-
ression with CsA and MMF, can result in reversal of
he disease phenotype in CLAD. The regimen de-
cribed in this article used matched littermate donors
from each dog at the designated intervals after transplantation, and
al antibody or an isotype control, as described in “Materials and
ere monitored clinically and treated for fever, pain, and infection
ndicated by a vertical line. Days with fever 103°F (39.4°C) arellected
noclonDogs w
ion is id. Last follow-up is indicated by an arrow.
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7nd resulted in mixed donor-host chimerism in all 3
LAD dogs. Two of the 3 dogs displayed donor
eukocyte chimerism of 10% to 15%, whereas the
hird dog had donor microchimerism of 1%. All 3
ogs are alive and well more than 1 year after trans-
lantation, having markedly exceeded the 6-month
ife expectancy of dogs with CLAD [7]. Two dogs are
linically indistinguishable from healthy littermates,
hereas the 1 dog with donor microchimerism has an
ttenuated CLAD phenotype resembling the moderate-
eﬁciency phenotype of LAD-1. These data indicate
hat a nonmyeloablative transplantation regimen
onsisting of chemotherapy and immunosuppression
ithout TBI can reverse the phenotype in CLAD.
Hematopoietic cell transplantation is the only cur-
tive therapy for LAD-1. Despite recent interest in
onmyeloablative and reduced-intensity conditioning
egimens, the standard of care for conditioning before
ransplantation for LAD-1 remains a myeloablative
egimen with its attendant toxicities [19]. In this set-
ing, signiﬁcant regimen-related toxicity and GVHD
emain major causes of morbidity and mortality and
imit the usefulness of transplantation [19]. In the
argest series of transplantations for LAD-1 reported
o date, which used a variety of myeloablative prepar-
tive regimens, 4 of 14 patients died, 5 of the 10
urvivors had grade II to IV acute GVHD, and 3 of
hose 5 had chronic GVHD [19].
We developed the CLAD model to test nonmy-
loablative transplantation regimens for the treatment
f LAD-1 [8,13,14]. The CLAD model recapitulates
he severe-deﬁciency LAD-1 phenotype, including
oorly healing skin lesions, leukocytosis, immunode-
ciency, gingivitis, and early death [8,20]. Moreover,
his model is particularly suited to the study of trans-
lantation for LAD-1, building on the extensive ex-
erience with dogs as a model for allogeneic trans-
lantation in general [21]. Prior studies from our
igure 5. Overall survival of control CLAD dogs and those that
nderwent transplantation. Curves were generated according to the
ethod of Kaplan and Meier. The upper curve represents the dogs
hat underwent transplantation, and the lower curve represents the
ontrol dogs. Squares represent last follow-up for living dogs. Cir-
les represent the time of death.aboratory have used nonmyeloablative conditioning L
60ith 200 cGy of TBI, followed by bone marrow trans-
lantation from DLA-identical littermates and immu-
osuppression with CsA and MMF, to induce stable
ixed chimerism and reversal of the CLAD pheno-
ype [10,14].
To investigate alternatives to TBI, we explored a
usulfan-based conditioning regimen before matched
ittermate transplantation in CLAD. Busulfan has not
reviously been used as a single agent in nonmyeloa-
lative transplantation regimens in humans; however,
everal considerations, both practical and theoretical,
ed to our choice of this drug. Of the 3 alkylating
gents most commonly used in pretransplantation
onditioning regimens—busulfan, cyclophosphamide,
nd melphalan—busulfan has most often been used as
replacement for TBI and has the longest history of
se in the pediatric population, which is the popula-
ion most likely to undergo nonmyeloablative trans-
lantation for LAD-1. Furthermore, busulfan has
een studied in autologous marrow transplantations in
ealthy dogs [16]. In those studies, marrow ablation
as achieved at a dose of 20 mg/kg, whereas 10 mg/kg
usulfan, the dose chosen for these studies, was found
o be nonmyeloablative [16]. Other agents commonly
sed in nonmyeloablative transplantation approaches
n humans, either with or without busulfan, are ﬂu-
arabine and anti–T-cell antibody preparations. Flu-
arabine is metabolized much more quickly in dogs
han it is in humans, thus making its use impractical
22]. With respect to antibodies, there is no experi-
nce with the anti-CD52 antibody alemtuzumab in
ogs. Antithymocyte or antilymphocyte serum has
een used previously; however, these reagents must be
ustom manufactured, and the preparations are more
ifﬁcult to standardize in dogs than in humans.
Because of the limitations of oral busulfan, we
hose to use the recently approved intravenous for-
ulation [23-25]. The initial experience with the in-
ravenous formulation showed that the pharmacoki-
etics were more predictable than those of the oral
ormulation of the drug [26-28]. In a clinical setting,
ntravenous administration of busulfan led to consis-
ent engraftment from related and unrelated donors.
Historically, LAD-1 patients have needed more
onditioning than other patients to achieve myeloab-
ation and facilitate engraftment. In particular, LAD-1
hildren have required the addition of etoposide to
tandard myeloablative doses of busulfan and cyclo-
hosphamide to reliably achieve engraftment and full
onor chimerism [19,29,30]. For this reason, there
as concern that the dose of busulfan that allows for
ngraftment in humans and dogs without LAD-1 or
LAD might be insufﬁciently myeloablative to lead to
ngraftment in CLAD dogs or in LAD-1 patients
ecause of the hyperexpanded bone marrow in both
AD-1 and CLAD. These studies were designed to
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Busulfan-Based Nonmyeloablative Bone Marrow Transplantation for CLAD
Bddress this issue in the disease-speciﬁc large-animal
odel of LAD-1.
Compared with ablative transplantations with or
ithout TBI, the busulfan conditioning regimen de-
cribed in this article was well tolerated. Leukopenia
id not occur, nor did thrombocytopenia or anemia
ecessitating transfusion. There were no infections
hat could not be easily managed with antibiotics.
here was no serious regimen-related toxicity. Long-
erm toxicity from busulfan was also not observed.
peciﬁcally, liver-associated enzymes have been nor-
al at all time points when they have been assayed,
xcept for a single asymptomatic increase of aspartate
minotransferase in Billie, and this level subsequently
pontaneously returned to normal. The dogs are able
o exercise to the same extent as carrier and wild-type
nimals, with no signs or symptoms of pulmonary
oxicity. Furthermore, none of the 3 dogs developed
VHD. In addition to being easily tolerated, this
egimen was effective, resulting in reversal of the
LAD phenotype in 2 dogs and its attenuation in the
hird animal.
One area of initial concern in our treated dogs was
he decline in donor chimerism in Frodo and Vixen
etween 100 and 350 days after transplantation. How-
ver, both dogs’ level of donor chimerism subse-
uently plateaued. This apparent decrease in chimer-
sm is consistent with delayed recovery of normal host
ematopoietic stem cells after treatment with busul-
an, rather than delayed graft rejection [31,32].
Partial chimerism is typically seen as problematic
n studies of nonmyeloablative transplantation, such
hat donor lymphocyte infusions have been used to
onvert to full donor chimerism even if the disease for
hich stem cell transplantation was indicated is no
onger evident [33]. These studies typically have been
n the setting of neoplastic disease, where one can
xpect—and where most experience has shown—that
ny residual host hematopoiesis will lead to disease
ecurrence [34-36]. This is not the case in primary
mmunodeﬁciency. LAD-1 patients with partial donor
himerism after allogeneic transplantation have rever-
al of the disease phenotype; this argues against the
eed for full donor chimerism, with the attendant
ncreased risk of GVHD, in this setting [19]. Previous
eports from our laboratory have examined the mini-
al level of donor chimerism necessary to reverse the
isease phenotype in CLAD [14]. Two dogs with only
0% CD18 white blood cells had complete reversal
f the CLAD phenotype. Even given these ﬁndings, it
s still somewhat surprising that Billie is able to survive
ith less than 1% CD18 cells only on prophylactic
ntibiotics. The most likely explanation is that the
D18 neutrophils in Billie selectively migrate into
issues, and, thus, measurement of CD18 neutrophils
n the peripheral blood may underestimate her tissue
eutrophils. This likely explains her benign clinical
B&MTourse. Also, because Billie has less than 1% CD18
ells in her marrow, it is accurate to refer to Billie as
aving less than 1% donor chimerism.
The mixed chimerism in the 3 dogs described in
his study may be one factor in the animals’ absence of
VHD. There is evidence that mixed chimerism is
olerogenic, and thus our dogs’ mixed chimerism may
xplain the lack of GVHD [37-39].
One limitation in the interpretation of our data is
he inbred nature of our colony. Considerable mea-
ures were taken at the outset to obtain genetic diver-
ity in our colony through breeding with unrelated
ild-type dogs at several early points in the develop-
ent of the colony [8]. Nevertheless, some increased
egree of homozygosity for minor histocompatibility
ntigens in excess of that seen in random outbred
arriers inherently exists in an inbred colony, despite
fforts to maintain genetic diversity. Our observations
f engraftment might be less consistent in large ani-
als from less inbred colonies or in humans. Further
tudies may be required in healthy dogs (more out-
red) that are not part of our CLAD colony.
In summary, these studies indicate that a prepar-
tive regimen of 10 mg/kg busulfan given as a single
ntravenous infusion allows engraftment of DLA-
dentical matched littermate bone marrow in dogs
ith CLAD. Levels of engraftment achievable with
his method are sufﬁcient to attenuate or reverse the
evere CLAD phenotype. Because this regimen did
ot lead to sufﬁcient levels of chimerism to completely
everse the CLAD phenotype in all 3 animals, addi-
ional agents may be required to translate this success
nto clinical application in settings where predictably
igher levels of donor chimerism are required and
here the degree of matching is more disparate than
n the canine model. Despite these caveats, the non-
yeloablative regimen described in this article results
n mixed chimerism and reversal or attenuation of the
isease phenotype in CLAD, thus suggesting that a
imilar approach may be clinically applicable in chil-
ren with LAD-1.
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